The role of α-Synuclein in neurodegenerative diseases: From molecular pathways in disease to therapeutic approaches

Current Alzheimer Research

Volumn 10, Issue 6, 2013, Pages 559-568

  Al Mansoori, Karima M ^a   Hasan, Mohamed Y ^a   Al Hayani, Abdulmonem ^b   El Agnaf, Omar M A ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alpha synuclein; Alzheimer's disease; Dementia with lewy bodies and protein aggregation; Drug discovery; Lewy bodies; Neurodegeneration; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; GAMMA SYNUCLEIN; GREEN TEA EXTRACT; HEAT SHOCK PROTEIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; PARKIN; RIFAMPICIN; SELEGILINE; TAU PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

ALZHEIMER DISEASE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CHEMICAL MODIFICATION; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; HAPLOTYPE; HUMAN; LEWY BODY; MISSENSE MUTATION; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NERVE ENDING; NITRATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION; TRANSCRIPTION INITIATION SITE; TRANSPORT VESICLE; UBIQUITINATION;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; HUMANS; LEWY BODIES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84882738891     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310060002     Document Type: Article

References (89)

1. Melcon MO, Anderson DW, Vergara RH, Rocca WA. Prevalence of Parkinson's disease in Junin, Buenos Aires Province, Argentina. Mov Disord 12: 197-205 (1997).
2. Lee FJ, Liu F. Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Res Rev 58: 354-64 (2008).
3. Schapira AHV. Science, medicine, and the future: Parkinson's disease. BMJ 318: 311-4 (1999).
4. Lewy FH. Paralysis agitans. Part I: Pathologische Anatomie. In: Lewandowsky M. Berlin: Springer (1912).
5. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology. 1990; 40: suppl 7-14; discussion-6-suppl 7-; discussion-6.
6. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the {alpha}-Synuclein Gene Identified in Families with Parkinson's Disease. Science 276: 2045-7 (1997).
7. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-8 (1998).
8. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Annal Neurol. 55: 164-73 (2004).
9. Chartier-Harlin M-C, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-9 (2004).
10. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841 (2003).
11. Tan EK, Chai A, Teo YY, Zhao Y, Tan C, Shen H, et al. Alphasynuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62: 128-131 (2004).
12. Chiba-Falek O, Touchman JW, Nussbaum RL. Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Human Genetics. 113: 426-31 (2003).
13. Linnertz C, Saucier L, Ge D, Cronin KD, Burke JR, Browndyke JN, et al. Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PloS One 4: e7480-e (2009).
14. Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA, et al. Alpha-synuclein and familial Parkinson's disease. Movement Disorders 24: 1125-31 (2009).
15. Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 57: 535-541 (2005).
16. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, et al. Genetic variability in the SNCA gene influences alphasynuclein levels in the blood and brain. FASEB J: Official Publication of the Federation of American Societies for Experimental Biology 22: 1327-1334 (2008).
17. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46: 1380-1388 (2007).
18. Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354: 422 (2006).
19. Change N, Mercier G, Lucotte G. Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. Genetic Testing 12: 333-9 (2008).
20. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Gene 41: 1303-1307 (2009).
21. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74: 197-109 (2010).
22. Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 26(9): 1593-604 (2011).
23. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Alphasynuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol 58(11): 1817-20 (2001).
24. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. Beta-amyloid peptides enhance alphasynuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98(21): 12245-50 (2001).
25. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619): 636-40 (2003).
26. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alphasynuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30(21): 7281-9 (2010).
27. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, et al. Soluble-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 32(30): 10253-66 (2012).
28. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Letters 345: 27-32 (1994).
29. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8: 2804-2815 (1988).
30. George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA, et al. Targeting the progression of Parkinson's disease. Current Neuropharmacology 7: 9-36 (2009).
31. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of-Synuclein Secondary Structure upon Binding to Synthetic Membranes. J Biol Chem 273: 9443-9449 (1998).
32. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acidbinding proteins. Proc Natl Acad Sci U S A 98: 9110-115 (2001).
33. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22: 8797-8807 (2002).
34. El-Agnaf OM, Bodles AM, Guthrie DJ, Harriott P, Irvine GB. The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur J Biochem 258: 157-63 (1998).
35. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type alphasynuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440: 71-75(1998).
36. Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 11: 1713-1723 (2004).
37. Lee D, Paik SR, Choi KY. Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein. FEBS Letters 576: 256-260 (2004).
38. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. Gamma-synuclein and the progression of cancer. FASEB J 21: 3419-3430 (2007).
39. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57: 759-764 (1997).
40. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, et al. Identification, localization and characterization of the human gamma-synuclein gene. Human Genetics 103: 106-112 (1998).
41. Buchman VL, Hunter HJ, Pinõn LG, Thompson J, Privalova EM, Ninkina NN, et al. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J Neurosci 18: 9335-9341 (1998).
42. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276: 2380-2386 (2001).
43. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8(5): 657-663 (2005).
44. Lee G, Tanaka M, Park K, Lee SS, Kim YM, Junn E, et al. Casein kinase II-mediated phosphorylation regulates alpha-synuclein /synphilin-1 interaction and inclusion body formation. J Biol Chem 279: 6834-6839 (2004).
45. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim H-Y, Lamberto GR, et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits {alpha}-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. J Neurosci 30: 3184-3 198 (2010).
46. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet 18(5): 872-887 (2008).
47. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102: 2162-2167 (2005).
48. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42: 8530-40 (2003).
49. Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O'Connell M, Ghetti B, et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26: 3942-50 (2006).
50. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15: 361-372 (1995).
51. Amer DA, Irvine GB, El-Agnaf OM. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res 173: 223-233 (2006).
52. El-Agnaf OM, Irvine GB. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J Struct Biol 130: 300-309 (2000).
53. Perrin RJ, Woods WS, Clayton DF, George JM. Interaction of Human-Synuclein and Parkinson's Disease Variants with Phospholipids. J Biol Chem 275: 34393-34398 (2000).
54. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214-3220 (2000).
55. Chandra S, Gallardo G, Fernndez-Chacun R, Schlter OM, Sdhof TC. [alpha]-Synuclein Cooperates with CSP[alpha] in Preventing Neurodegeneration. Cell 123: 383-396 (2005).
56. Kim TD, Paik SR, Yang CH. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41: 13782-13790 (2002).
57. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276: 10737-10744 (2001).
58. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 799: 301-306 (1998).
59. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9: 2683-2689 (2000).
60. Martin FL, Williamson SJ, Paleologou KE, Hewitt R, El-Agnaf OM, Allsop D. Fe(II)-induced DNA damage in alpha-synucleintransfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay. J Neurochem 87: 620-630 (2003).
61. Stefanis L, Kholodilov N, Rideout HJ, Burke RE, Greene LA. Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J Neurochem 76: 1165-1176 (2001).
62. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17(13): 1945-1947 (2003).
63. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, et al. CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 283: 17962-17968 (2008).
64. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30(20): 6838-6851 (2010).
65. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 7: 42 (2012).
66. El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, et al. A strategy for designing inhibitors of alphasynuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 18: 1315-1317 (2004).
67. Huggins KN, Bisaglia M, Bubacco L, Tatarek-Nossol M, Kapurniotu A, Andersen NH. Designed hairpin peptides interfere with amyloidogenesis pathways: fibril formation and cytotoxicity inhibition, interception of the preamyloid state. Biochemistry 50(38): 8202-8212 (2011).
68. Hosia W, Bark N, Liepinsh E, Tjernberg A, Persson B, Hallén D, et al. Folding into a beta-hairpin can prevent amyloid fibril formation. Biochemistry 43: 4655-4661 (2004).
69. Fan Y, Limprasert P, Murray IVJ, Smith AC, Lee VMY, Trojanowski JQ, et al. {beta}-synuclein modulates {alpha}-synuclein neurotoxicity by reducing {alpha}-synuclein protein expression. Hum Mol Genet 15: 3002-3011 (2006).
70. Mor F, Quintana F, Mimran A, Cohen IR. Autoimmune encephalomyelitis and uveitis induced by T cell immunity to self betasynuclein. Journal of Immunology (Baltimore, Md: 1950). 170: 628-34 (2003).
71. Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med 43: 216-222 (2011).
72. Hasegawa T, Matsuzaki-Kobayashi M, Takeda A, Sugeno N, Kikuchi A, Furukawa K, et al.-Synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease. FEBS Lett 580: 2147-2152 (2006).
73. Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: Evolutionary and Ecological Physiology. Ann Rev Physio 61: 243-282 (1999).
74. Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111: 1543-1573 (2004).
75. Auluck PK, Chan HYE, Trojanowski JQ, Lee VMY, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (New York, NY) 295: 865-868 (2002).
76. Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, et al. Hsp104 antagonizes-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118: 3087-3097 (2008).
77. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, et al. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synucleininduced toxicity. J Pharmacol Exp Ther 332: 849-857 (2010).
78. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synucleinmediated toxicity in models of Parkinson's disease. Science 317: 516-519 (2007).
79. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin Inhibits-Synuclein Fibrillation and Disaggregates Fibrils. Chem Biol 11: 1513-1521 (2004).
80. Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 19: 1271-1276 (2008).
81. Martinez Z, Zhu M, Han S, Fink AL. GM1 specifically interacts with-synuclein and inhibits fibrillation. Biochemistry 46: 1868-1877 (2007).
82. Braga CA, Follmer C, Palhano FL, Khattar E, Freitas MS, Romao L, et al. The anti-Parkinsonian drug selegiline delays the nucleation phase of alpha-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol 405: 254-273 (2011).
83. Frydman-Marom A, Shaltiel-Karyo R, Moshe S, Gazit E. The generic amyloid formation inhibition effect of a designed small aromatic-breaking peptide. Amyloid 18: 119-127 (2011).
84. Ross NT, Metkar SR, Le H, Burbank J, Cahill C, Germain A, et al. Identification of a small molecule that selectively inhibits alphasynuclein translational expression. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2011 (2011).
85. Lu JH, Ardah MT, Durairajan SSK, Liu LF, Xie LX, Fong WFD, et al. Baicalein Inhibits Formation of Synuclein Oligomers within Living Cells and Prevents A Peptide Fibrillation and Oligomerisation. ChemBioChem 12: 615-624 (2011).
86. Di Giovanni S, Eleuteri S, Paleologou KE, Yin G, Zweckstetter M, Carrupt P-A, et al. Entacapone and tolcapone, two catechol Omethyltransferase inhibitors, block fibril formation of alphasynuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem 285: 14941-14954 (2010).
87. Lamberto GR, Torres-Monserrat V, Bertoncini CW, Salvatella X, Zweckstetter M, Griesinger C, et al. Towards the discovery of effective polycyclic inhibitors of alpha-Synuclein amyloid assembly. J Biol Chem 286(37): 32036-44 2011.
88. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15: 558-566 (2008).
89. Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 3: 194-208 (2010).